Utilizing gene therapy to target cancer and mutated cells
Raised to Date: $1,069,890
Aggregate Commitments $
Equity - Common
Weekly Commitments $
PhorMed, with a pre-money valuation of $39 million, is raising funds on StartEngine.It is a biopharmaceutical company that is changing the face of genomic medicine. PhorMed uses gene therapy to target and treat cancer cells and mutated cells, and develops a treatment for patients suffering from Hodgkin’s Lymphoma, Parkinson’s Disease, and Acute Myeloid Leukemia. PhorMed was founded by McCoy Moretz Richard L. Chang and others. The proceeds of the current crowdfunding round, with a minimum target of $10,000 and a maximum target of $107,000, will be used for the Phase 2 clinical trials of the drug. PhorMed uses a leading technology, RP-323, as its gene repair therapy. The drug has completed Phase 1 of the clinical study and has generated positive outcomes.